548 1024

Cited 18 times in

[18F]-Fluorodeoxyglucose Positron Emission Tomography Can Contribute to Discriminate Patients with Poor Prognosis in Hormone Receptor-Positive Breast Cancer.

 Sung Gwe Ahn  ;  Minkyung Lee  ;  Tae Joo Jeon  ;  Kyunghwa Han  ;  Hak Min Lee  ;  Seung Ah Lee  ;  Young Hoon Ryu  ;  Eun Ju Son  ;  Joon Jeong 
 PLOS ONE, Vol.9(8) : e105905, 2014 
Journal Title
Issue Date
Adult ; Aged ; Aged, 80 and over ; Breast Neoplasms/diagnostic imaging* ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology* ; Female ; Fluorodeoxyglucose F18* ; Humans ; Ki-67 Antigen/metabolism ; Middle Aged ; Prognosis ; Radiopharmaceuticals* ; Receptor, ErbB-2/metabolism* ; Survival Analysis ; Tomography, Emission-Computed, Single-Photon
BACKGROUND: Patients with hormone receptor-positive breast cancer typically show favorable survival. However, identifying individuals at high risk of recurrence among these patients is a crucial issue. We tested the hypothesis that [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) scans can help predict prognosis in patients with hormone receptor-positive breast cancer.
METHODS: Between April 2004 and December 2008, 305 patients with hormone receptor-positive breast cancer who underwent FGD-PET were enrolled. Patients with luminal B subtype were identified by positivity for human epidermal growth factor receptor-2 (HER2) or high Ki67 (≥14%) according to criteria recently recommended by the St. Gallen panelists. The cut-off value of SUVmax was defined using the time-dependent receiver operator characteristic curve for recurrence-free survival (RFS).
RESULTS: At a median follow up of 6.23 years, continuous SUVmax was a significant prognostic factor with a hazard ratio (HR) of 1.21 (p = 0.021). The cut-off value of SUVmax was defined as 4. Patients with luminal B subtype (n = 82) or high SUVmax (n = 107) showed a reduced RFS (p = 0.031 and 0.002, respectively). In multivariate analysis for RFS, SUVmax carried independent prognostic significance (p = 0.012) whereas classification with immunohistochemical markers did not (p = 0.274). The Harell c-index was 0.729. High SUVmax was significantly associated with larger tumor size, positive nodes, HER2 positivity, high Ki67 (≥14%), high tumor grade, and luminal B subtype.
CONCLUSIONS: Among patients with hormone receptor-positive breast cancer, FDG-PET can help discriminate patients at high risk of tumor relapse.
Files in This Item:
T201402616.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Research Institute (부설연구소) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Nuclear Medicine (핵의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Son, Eun Ju(손은주) ORCID logo https://orcid.org/0000-0002-7895-0335
Ahn, Sung Gwe(안성귀) ORCID logo https://orcid.org/0000-0002-8778-9686
Ryu, Young Hoon(유영훈) ORCID logo https://orcid.org/0000-0002-9000-5563
Lee, Min Kyung(이민경)
Lee, Hak Min(이학민)
Jeon, Tae Joo(전태주) ORCID logo https://orcid.org/0000-0002-7574-6734
Jeong, Joon(정준) ORCID logo https://orcid.org/0000-0003-0397-0005
Han, Kyung Hwa(한경화)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.